Validation of a routine opsonophagocytosis assay to predict invasive pneumococcal disease efficacy of conjugate vaccine in children

被引：81

作者：

Henckaerts, Isabelle ^{[1
]}

Durant, Nathalie ^{[1
]}

De Grave, Dany ^{[1
]}

Schuerman, Lode ^{[1
]}

Poolman, Jan ^{[1
]}

机构：

[1] GlaxoSmithKline Biol, Res & Dev, B-1330 Rixensart, Belgium

来源：

VACCINE | 2007年 / 25卷 / 13期

关键词：

pneumococcal conjugate vaccine; opsonophagocytic antibodies; assay validation;

D O I：

10.1016/j.vaccine.2006.09.029

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Immunological evaluation of the clinical impact of vaccines designed to protect against infection by Streptococcus pneumoniae requires measurement of serotype-specific functional antibodies. We describe the development and validation of a viable pneumococcal opsonophagocytosis assay (OPA) that can be used for routine serological analysis of paediatric immune responses after immunization. OPA seropositivity (% >= 8 threshold) reflected well invasive pneumococcal disease (IPD) effectiveness. In contrast, the 22F inhibition ELISA seropositivity (% >= 0.20 mu g/ml threshold) overestimated (19F) or underestimated (6B, 23F, 6A) IPD effectiveness for several serotypes. The seropositivity as estimated by a standardized and highly reproducible OPA was predictive for the serotype-specific IPD efficacy of pneumococcal conjugate vaccines. (C) 2006 Published by Elsevier Ltd.

引用

页码：2518 / 2527

页数：10

共 39 条

[1]

Abramson JS, 2000, PEDIATRICS, V106, P362

[2]

Addae-Mensah I, 2005, WHO TECH REP SER, V929, P1

[3] STREPTOCOCCUS-PNEUMONIAE - VIRULENCE FACTORS, PATHOGENESIS, AND VACCINES [J].

ALONSODEVELASCO, E ;

VERHEUL, AFM ;

VERHOEF, J ;

SNIPPE, H .

MICROBIOLOGICAL REVIEWS, 1995, 59 (04) :591-&

[4]

ANDERSON PW, 1986, J IMMUNOL, V137, P1181

[5] Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente [J].

Black, S ;

Shinefield, H ;

Baxter, R ;

Austrian, R ;

Bracken, L ;

Hansen, J ;

Lewis, E ;

Fireman, B .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2004, 23 (06) :485-489

[6] Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children [J].

Black, S ;

Shinefield, H ;

Fireman, B ;

Lewis, E ;

Ray, P ;

Hansen, JR ;

Elvin, L ;

Ensor, KM ;

Hackell, J ;

Siber, G ;

Malinoski, F ;

Madore, D ;

Chang, I ;

Kohberger, R ;

Watson, W ;

Austrian, R ;

Edwards, K .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2000, 19 (03) :187-195

[7] Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia [J].

Black, SB ;

Shinefield, HR ;

Ling, S ;

Hansen, J ;

Fireman, B ;

Spring, D ;

Noyes, J ;

Lewis, E ;

Ray, P ;

Lee, J ;

Hackell, J .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2002, 21 (09) :810-815

[8] Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine [J].

Black, SB ;

Shinefield, HR ;

Hansen, J ;

Elvin, L ;

Laufer, D ;

Malinoski, F .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2001, 20 (12) :1105-1107

[9]

*CDCP, 1994, MMWR-MORBID MORTAL W, V43, P144

[10]

CONCEPCION N, 2002, INT S PNEUM PNEUM DI

← 1 2 3 4 →